Loading...
34 antiandrogen COVID-19 controlled studies, 10 RCTs
https://c19early.com/aameta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 77%
0.23 [0.08-0.66]
recov. time
8 (n)
262 (n)
Improvement, RR [CI] Treatment Control Cadegiani 83%
0.17 [0.06-0.51]
recov. time
8 (n)
262 (n)
Cadegiani 38%
0.62 [0.42-0.91]
viral time
8 (n)
262 (n)
Cadegiani (DB RCT) 62%
0.38 [0.18-0.82]
no recov.
7/44
18/43
Cadegiani (DB RCT) 44%
0.56 [0.40-0.79]
recov. time
44 (n)
43 (n)
Cadegiani (DB RCT) 40%
0.60 [0.44-0.81]
recov. time
44 (n)
43 (n)
Vicenzi 93%
0.07 [0.04-0.53]
death
30 (n)
39 (n)
OT1
Vicenzi 81%
0.19 [0.07-0.53]
death/int.
30 (n)
39 (n)
OT1
Goren 81%
0.19 [0.03-1.28]
ICU
1/12
17/36
Goren 86%
0.14 [0.02-0.94]
ICU
1/12
38/65
Goren -50%
1.50 [0.15-15.1]
death
1/12
2/36
Goren -35%
1.35 [0.17-11.1]
death
1/12
4/65
Mareev (RCT) 11%
0.89 [0.65-1.22]
no recov.
33 (n)
33 (n)
CT2
Mareev (RCT) 39%
0.61 [0.14-0.97]
no disch.
14/24
20/21
CT2
Mareev (RCT) 8%
0.92 [0.77-1.09]
hosp. time
33 (n)
33 (n)
CT2
Mareev (RCT) 87%
0.13 [0.01-2.25]
viral+
0/17
3/13
CT2
Zarehoseinz.. (RCT) 75%
0.25 [0.03-2.14]
death
1/40
4/40
Zarehoseinz.. (RCT) 0%
1.00 [0.06-15.4]
ICU
1/40
1/40
Ersoy (ICU) 46%
0.54 [0.36-0.81]
death
14/30
26/30
ICU patients
Welén (RCT) 80%
0.20 [0.01-4.65]
death
0/29
1/10
Welén (RCT) 31%
0.69 [0.07-6.81]
ventilation
2/29
1/10
Welén (RCT) -133%
2.33 [1.06-5.00]
no disch.
29 (n)
10 (n)
Welén (RCT) -50%
1.50 [1.10-2.04]
hosp. time
29 (n)
10 (n)
Davarpanah 78%
0.22 [0.08-0.55]
hosp.
6/103
23/103
CT2
Davarpanah 64%
0.36 [0.21-0.60]
recov. time
103 (n)
103 (n)
CT2
Kotfis (RCT) 17%
0.83 [0.25-2.74]
death
4/24
5/25
Kotfis (RCT) 11%
0.89 [0.35-2.28]
ICU
6/24
7/25
Kotfis (RCT) 30%
0.70 [0.24-2.01]
TFS
24 (n)
25 (n)
Abbasi (SB RCT) 55%
0.45 [0.18-1.13]
death
5/51
19/87
Abbasi (SB RCT) 34%
0.66 [0.30-1.48]
ventilation
7/51
18/87
Abbasi (SB RCT) 19%
0.81 [0.42-1.59]
ICU
10/51
21/87
Abbasi (SB RCT) 47%
0.53 [0.39-0.72]
no recov.
51 (n)
87 (n)
Gomaa (DB RCT) 91%
0.09 [0.01-1.56]
death
0/25
5/25
CT2
Gomaa (DB RCT) 91%
0.09 [0.01-1.56]
ventilation
0/25
5/25
CT2
Gomaa (DB RCT) 44%
0.56 [0.40-0.79]
recov. time
25 (n)
25 (n)
CT2
Gomaa (DB RCT) 33%
0.67 [0.52-0.85]
no recov.
25 (n)
25 (n)
CT2
Hsieh 88%
0.12 [0.01-2.22]
death
0/117
4/143
CT2
Hsieh 51%
0.49 [0.10-2.47]
ventilation
2/117
5/143
CT2
Hsieh 30%
0.70 [0.21-2.33]
ICU
4/117
7/143
CT2
Hsieh 88%
0.12 [0.01-2.22]
no recov.
0/117
4/143
CT2
Hsieh 36%
0.64 [0.51-0.80]
viral load
117 (n)
143 (n)
CT2
Veru (DB RCT) 54%
0.46 [0.28-0.76]
death
20/98
23/52
Nickols (DB RCT) 18%
0.82 [0.32-1.82]
death
11/62
7/34
Nickols (DB RCT) -19%
1.19 [0.50-2.84]
ventilation
13/62
6/34
Nickols (DB RCT) -17%
1.17 [0.50-2.28]
no recov.
15/62
7/34
Nickols (DB RCT) -20%
1.20 [0.02-92.1]
hosp. time
62 (n)
34 (n)
Gordon (DB RCT) 82%
0.18 [0.03-0.94]
death
n/a
n/a
Gordon (DB RCT) 76%
0.24 [0.03-1.63]
ventilation time
n/a
n/a
Gordon (DB RCT) 73%
0.27 [0.09-0.86]
ICU
n/a
n/a
Montopoli 95%
0.05 [0.00-0.77]
death
0/5,273
18/37,161
Montopoli 75%
0.25 [0.09-0.76]
severe case
1/5,273
31/37,161
Montopoli 75%
0.25 [0.09-0.65]
cases
4/5,273
114/37,161
Koskinen 46%
0.54 [0.06-5.16]
death
1/134
3/218
Koskinen 46%
0.54 [0.06-5.16]
death/ICU
1/134
3/218
Koskinen 11%
0.89 [0.34-2.34]
cases
6/134
11/218
Patel 55%
0.45 [0.11-1.47]
death
4/22
10/36
Patel 69%
0.31 [0.05-1.81]
ventilation
22 (n)
36 (n)
Patel 77%
0.23 [0.06-0.79]
hosp.
22 (n)
36 (n)
Bennani 95%
0.05 [0.00-2063]
death
0/4
18/114
Bennani -119%
2.19 [0.37-12.9]
ICU
1/4
13/114
Bennani 25%
0.75 [0.28-2.02]
hosp.
2/4
76/114
Bennani 8%
0.92 [0.16-5.15]
severe case
1/4
31/114
Lazzeri -23%
1.23 [0.81-1.87]
death/ICU
Kwon 21%
0.79 [0.10-6.40]
death
1/799
7/4,412
Kwon -18%
1.18 [0.70-1.96]
cases
18/799
79/4,412
Klein -124%
2.24 [0.86-5.85]
death
6/304
13/1,475
Klein 7%
0.93 [0.55-1.56]
cases
17/304
85/1,475
Jeon 77%
0.23 [0.08-0.64]
cases
case control
Shaw (PSM) 6%
0.94 [0.88-1.01]
cases
47 (n)
97 (n)
Jiménez-Alcaide 33%
0.67 [0.26-1.74]
death
3/11
17/50
Jiménez-Alcaide -8%
1.08 [0.54-1.83]
progression
11 (n)
50 (n)
Jiménez-Alcaide -68%
1.68 [0.90-3.16]
cases
11/156
50/1,193
Kazan -229%
3.29 [0.61-17.7]
hosp.
4/138
2/227
Kazan 29%
0.71 [0.39-1.32]
cases
13/138
30/227
Schmidt (PSM) 20%
0.80 [0.46-1.34]
death
25/169
44/308
Schmidt (PSM) 2%
0.98 [0.61-1.56]
severe case
169 (n)
308 (n)
Duarte 11%
0.89 [0.59-1.11]
death
100/156
32/43
Welén 2%
0.98 [0.61-1.59]
death
21/358
167/4,980
Welén 11%
0.89 [0.54-1.46]
death
20/334
167/4,980
Welén -151%
2.51 [1.52-4.16]
death
24/152
167/4,980
Welén -28%
1.28 [0.82-1.99]
ICU
24/358
216/4,980
Welén 13%
0.87 [0.51-1.48]
ICU
16/334
216/4,980
Welén 21%
0.79 [0.34-1.86]
ICU
6/152
216/4,980
Welén -23%
1.23 [0.96-1.56]
hosp.
126/358
1,108/4,980
Welén -24%
1.24 [0.97-1.59]
hosp.
126/334
1,108/4,980
Welén -40%
1.40 [0.98-1.99]
hosp.
66/152
1,108/4,980
Gedeborg -25%
1.25 [0.95-1.65]
death
case control
Lyon 17%
0.83 [0.42-1.63]
death
15/944
19/994
Lyon 7%
0.93 [0.86-1.00]
cases
399/944
446/994
Lee (IPW) 21%
0.79 [0.62-0.97]
severe case
76/295
727/2,427
Lee (IPW) 11%
0.89 [0.82-0.95]
cases
295/3,057
2,427/36,096
MacFadden 7%
0.93 [0.88-0.98]
cases
n/a
n/a
antiandrogen COVID-19 outcomes c19early.com/aa May 2022
1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors antiandrogen
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit
